Celltrion Healthcare, Stock Price Down 3.23% at This Hour... 1,161,965 Shares Net Sold by Individuals in Last 5 Days

As of 11:31 AM on the 14th, Celltrion Healthcare is trading at 104,700 KRW, down 3.23% from the previous day. The trading volume is 2,124,054 shares, which is about 27.76% of the previous day's volume. Celltrion Healthcare is known as the exclusive distributor of Celltrion's biosimilars.

On August 14th, NH Investment & Securities researcher Koo Wan-sung stated, "We maintain our Top-pick rating on the bio sector. As of June, Truxima's market share in the U.S. reached approximately 16.4%. The increase in the sales proportion of the highly profitable Truxima has led to a MIX improvement effect, resulting in double-digit OPM for three consecutive quarters. Second-quarter sales of Remsima SC are estimated at about 8.4 billion KRW. In July, Remsima SC received EMA approval in Europe for all indications, including IBD (inflammatory bowel disease). With the full-scale prescription of Remsima SC in the second half of the year, strong performance is expected to continue." He set the target price for Celltrion Healthcare at 130,000 KRW.

Over the past five days, individual investors have net sold 1,161,965 shares of Celltrion Healthcare, while foreigners and institutions have net bought 445,965 shares and 748,029 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.